Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: A time series analysis

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Manns, Braden ^a,b,c,d   Laupland, Kevin ^a,b   Tonelli, Marcello ^d,e   Gao, Song ^d   Hemmelgarn, Brenda ^a,b,c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Division of Nephrology   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibiotic; Formulary restriction; Prescription drugs; Prior authorization

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

AGED; ARTICLE; CANADA; CLINICAL PRACTICE; DRUG UTILIZATION; ECONOMICS; EVALUATION; FEMALE; HUMAN; INSURANCE; MALE; OUTPATIENT; PRESCRIPTION; PUBLICATION; REGRESSION ANALYSIS; REIMBURSEMENT; STATISTICAL MODEL; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBERTA; ANTI-BACTERIAL AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FORMULARIES AS TOPIC; HUMANS; LINEAR MODELS; MALE; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; QUINOLONES; REGRESSION ANALYSIS; REIMBURSEMENT MECHANISMS; UNIVERSAL COVERAGE;

EID: 84865454724     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-290     Document Type: Article

References (23)

1. CIHI, Health Care in Canada Toronto: CIHI 2002
2. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. Fischer MA, Schneeweiss S, Avorn J, Solomon DH, N Engl J Med 2004 351 2187 2194 10.1056/NEJMsa042770 15548779
3. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska. Siracuse MV, Vuchetich PJ, Health Serv Res 2008 43 435 450 10.1111/j.1475-6773.2007.00766.x 18199195
4. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J, BMJ 2004 328 560 10.1136/bmj.38020.698194.F6 14982865
5. Impact of a criteria-based reimbursement policy on the use of respiratory drugs delivered by nebulizer and health care services utilization in Nova Scotia, Canada. Kephart G, Sketris IS, Bowles SK, Richard ME, Cooke CA, Pharmacotherapy 2005 25 1248 1257 10.1592/phco.2005.25.9.1248 16164398
6. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. McCombs JS, Shi L, Stimmel GL, Croghan TW, Clin Ther 2002 24 1939 1959 discussion 8. 10.1016/S0149-2918(02)80090-X 12501884
7. Perceptions of Saskatchewan community pharmacists regarding a prior-authorization program. Perepelkin J, Dobson RT, J Manag Care Pharm 2007 13 589 597 17874865
8. Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs. Fischer MA, Polinski JM, Servi AD, Agnew-Blais J, Kaci L, Solomon DH, Arthritis Rheum 2008 59 1611 1617 10.1002/art.24191 18975371
9. Prospective survey of antibiotic utilization in pediatric hospitalized patients to identify targets for improvement of prescription. Potocki M, Goette J, Szucs TD, Nadal D, Infection 2003 31 398 403 14735382
10. Antibacterial resistance worldwide: causes, challenges and responses. Levy SB, Marshall B, Nat Med 2004 10 122 S129 10.1038/nm1145 15577930
11. Conly J, Antimicrobial resistance in Canada. Cmaj 2002 167 885 891
12. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB, Clin Infect Dis 1997 25 230 239 10.1086/514545 9332517
13. Antibiotic armageddon. Kunin CM, Clin Infect Dis 1997 25 240 241 10.1086/514544 9332518
14. When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians. Kahan NR, Chinitz DP, Waitman DA, Kahan E, Br J Clin Pharmacol 2006 61 341 344 10.1111/j.1365-2125.2006.02577.x 16487229
15. Segmented regression analysis of interrupted time series studies in medication use research. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D, J Clin Pharm Ther 2002 27 299 309 10.1046/j.1365-2710.2002.00430.x 12174032
16. Longitudinal data analysis for discrete and continuous outcomes. Zeger SL, Liang KY, Biometrics 1986 42 121 130 10.2307/2531248 3719049
17. A case study on the choice, interpretation and checking of multilevel models for longitudinal binary outcomes. Carlin JB, Wolfe R, Brown CH, Gelman A, Biostatistics 2001 2 397 416 10.1093/biostatistics/2.4.397 12933632
18. Comparison of population-averaged and subject-specific approaches for analyzing repeated binary outcomes. Hu FB, Goldberg J, Hedeker D, Flay BR, Pentz MA, Am J Epidemiol 1998 147 694 703 10.1093/oxfordjournals.aje.a009511 9554609
19. Carroll N, Application of segment regression analysis to the Kaiser Permanente Colorado Critical Drug Interaction Program Denver, CO: Kaiser Permanente 2006
20. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". Avorn J, Soumerai SB, N Engl J Med 1983 308 1457 1463 10.1056/NEJM198306163082406 6406886
21. Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial. Dormuth CR, Maclure M, Bassett K, Jauca C, Whiteside C, Wright JM, CMAJ 2004 171 1057 1061 10.1503/cmaj.1031621 15505268
22. Improving antibiotic utilization among hospitalists: a pilot academic detailing project with a public health approach. Kisuule F, Wright S, Barreto J, Zenilman J, J Hosp Med 2008 3 64 70 10.1002/jhm.278 18257048
23. Interventions to improve antibiotic prescribing practices in ambulatory care. Arnold SR, Straus SE, Cochrane Database Syst Rev 2005 19 4 D003539